Your browser doesn't support javascript.
loading
Effectiveness of antibacterial prophylaxis with non-absorbable polymyxin B compared to levofloxacin after allogeneic hematopoietic stem cell transplantation.
Koh, S; Yamada, K; Nishimoto, M; Hayashi, Y; Koh, H; Nakashima, Y; Nakane, T; Hirose, A; Nakamae, M; Kakeya, H; Hino, M; Nakamae, H.
Afiliação
  • Koh S; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Yamada K; Infection Control Science, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Nishimoto M; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Hayashi Y; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Koh H; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Nakashima Y; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Nakane T; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Hirose A; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Nakamae M; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Kakeya H; Infection Control Science, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Hino M; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
  • Nakamae H; Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Transpl Infect Dis ; 17(5): 647-54, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26134140
BACKGROUND: Fluoroquinolones are widely used for antibacterial prophylaxis during neutropenia following hematopoietic stem cell transplantation (HSCT). Nevertheless, data are inadequate as to whether fluoroquinolones decrease mortality rate compared with other antibiotics. METHODS: We retrospectively compared the efficacy of antibacterial prophylaxis using non-absorbable polymyxin B (PB) (n = 106) or systemic levofloxacin (LVFX) (n = 140) after allogeneic SCT at our institute between 2004 and 2013. RESULTS: No significant difference was observed between the 2 groups in the cumulative incidences of failure of prophylaxis (P = 0.21), clinically documented infections (P = 0.70), or non-relapse mortality within the first 100 days after transplantation (P = 0.42). With bacteremia, the rate of resistance to LVFX was 82% in the PB group and 100% in the LVFX group (P = 0.41). Also, no significant difference was found in overall survival between the 2 groups (P = 0.78). CONCLUSION: Our results indicate no difference in the effectiveness of antibacterial prophylaxis between systemic antibiotic LVFX and non-absorbable antibiotic PB.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimixina B / Infecções Bacterianas / Infecções Oportunistas / Transplante de Células-Tronco Hematopoéticas / Antibioticoprofilaxia / Levofloxacino / Antibacterianos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimixina B / Infecções Bacterianas / Infecções Oportunistas / Transplante de Células-Tronco Hematopoéticas / Antibioticoprofilaxia / Levofloxacino / Antibacterianos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article